Onartuzumab
- Generic Name
- Onartuzumab
- Drug Type
- Biotech
- CAS Number
- 1133766-06-9
- Unique Ingredient Identifier
- MS1J9720WC
- Background
Onartuzumab has been used in trials studying the treatment of Neoplasms, Lung Cancer, Glioblastoma, Gastric Cancer, and Colorectal Cancer, among others.
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- Drug: PlaceboDrug: cisplatin/carboplatin
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 259
- Registration Number
- NCT01496742
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
Phase 3
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 494
- Registration Number
- NCT01456325
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- Drug: FOLFOX regimenDrug: Placebo
- First Posted Date
- 2011-08-17
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 194
- Registration Number
- NCT01418222
- Locations
- 🇺🇸
Ingalls Cancer Research Center, Harvey, Illinois, United States
🇺🇸Toledo Comm. Onc. Program, Toledo, Ohio, United States
🇺🇸Virginia Cancer Institute, Richmond, Virginia, United States
Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 185
- Registration Number
- NCT01186991
- Locations
- 🇺🇸
Can Care Assoc Med Group Inc; Beach Cities Offices, Los Angeles, California, United States
🇺🇸Comprehensive Blood/Cancer Ctr, Bakersfield, California, United States
🇺🇸St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr, Fullerton, California, United States
A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT01068977
A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)
Phase 2
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2009-03-03
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 137
- Registration Number
- NCT00854308
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath